A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease

Trial Profile

A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms MINDSET Extension
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 15 Aug 2016 According to an Axovant Sciences media release, secondary analyses from this trial will assess changes to patient scores on the Dependence Scale. Various background therapies, including cholinesterase inhibitors and memantine will be allowed during the trial
    • 11 May 2016 Status changed from not yet recruiting to recruiting.
    • 30 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top